AstraZeneca PLC
AZN Real Time Price USDRecent trades of AZN by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in AZN holdings by institutional investors
Quarterly net insider trading by AZN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$810,000 Oct 20, 2026 Issue: Health Issues Labor Issues/Antitrust/Workplace Medicare/Medicaid Pharmacy Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Insurance Manufacturing
-
$1,680,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid Pharmacy Copyright/Patent/Trademark Tariff (miscellaneous tariff bills) Trade (domestic/foreign) Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code
-
$2,280,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills) Trade (domestic/foreign)
-
$670,000 Jan 20, 2026 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$1,350,000 Oct 17, 2025 Issue: Pharmacy Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$1,840,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$1,240,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$640,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Insurance
-
$650,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$950,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$80,000 Feb 07, 2024 Issue: Health Issues Medicare/Medicaid Pharmacy Budget/Appropriations
-
$830,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$950,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
Former government officials who have lobbied for AZN
63 former government officials from 38 congressional offices at 11 lobbying firms have lobbied for AZN, most recently Oct 20, 2026.
-
Raissa Downs Senate Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Staff Dir., Sub. Cmte. on Employment, Sen. HELP Cmte.
-
Jennifer Young Congress Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff, Sen. Cmte. on Finance
-
Elizabeth Murray House Senior Policy Advisor, Democratic Whip Steny Hoyer; Legislative Asst. for Rep. Mike Thompson, Rep. Bob Matsui, and Senator Bob Graham -
Charlotte Ivancic Senate Legislative Counsel, Senator Jim DeMint; Health Counsel, Majority Leader Bill Frist; Counsel and Budget Analyst, House Budget Committee; Asst. to the Speaker for Policy, Speaker John Boehner -
Pamela Smith Senate Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Senate HELP Cmte; Staff Dir., Senate HELP Cmte; Counselor to the Asst. AG, Civil Div., Dept of Justice; Spec Counsel, Ofc of Leg. Affairs, Dept of Justice; Counsel and LA, Senator Carol Moseley-Braun -
Emily Murry House Staff Dir., Sub. Cmte. on Health, W&M Cmte; Sr. Policy Advisor, Majority Leader McCarthy; Policy Advisor, Majority Whip McCarthy; Professional Staff, Republican Study Cmte.; Leg. Aid, Rep. Ken Calvert; Leg. Asst., Rep. Tom Price
-
Margaret Joseph Senate CoS for Sen. Kyrsten Sinema, CoS for Rep. Kyrsten Sinema, CoS for Rep. Bobby Bright, CoS for Rep. Jim Matheson, Clerk for House Rules Cmte. -
Peter Fise Congress Health Counsel for Sen. Cmte on Finance, Health Counsel for Sen. Jeanne Shaheen, Staff Assistant for House Cmte on Oversight & Government Reform
AZN Estimated quarterly lobbying spending
AZN Revenue by Segment or Geography
New AZN patent grants
-
Patent Title: Chemical compounds 542 May. 26, 2015
-
Patent Title: Ethanamine compounds and methods of using the same May. 19, 2015
-
Patent Title: Cyclopropyl amide derivatives May. 12, 2015
-
Patent Title: Chromenone derivatives May. 12, 2015
-
Patent Title: Chemical compounds Apr. 28, 2015
-
Patent Title: Phosphonoxy quinazoline derivatives and their pharmaceutical use Apr. 28, 2015
-
Patent Title: Crystalline naloxol-peg conjugate Apr. 21, 2015
-
Patent Title: 2-carboxamide-4-piperazinyl-benzofuran derivative Apr. 21, 2015
-
Patent Title: Processes for making cyclopropyl amide derivatives and intermediates associated therewith Apr. 21, 2015
-
Patent Title: Cycloalkyl ether compounds and their use as bace inhibitors Apr. 07, 2015
-
Patent Title: Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as bace inhibitors Apr. 07, 2015
-
Patent Title: Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as bace inhibitors Apr. 07, 2015
-
Patent Title: 2h-imidazol-4-amine compounds and their use as bace inhibitors Apr. 07, 2015
-
Patent Title: Chemical compounds Apr. 07, 2015
-
Patent Title: Cyclopropyl amide derivatives Mar. 31, 2015
-
Patent Title: 9-substituted 8-oxoadenine compound Mar. 03, 2015
-
Patent Title: Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient Mar. 03, 2015
-
Patent Title: 2-(2,4,5-substituted-anilino) pyrimidine compounds Feb. 03, 2015
-
Patent Title: Phenyl and benzodioxinyl substituted indazoles derivatives Dec. 23, 2014
-
Patent Title: Chemical compounds 251 Dec. 02, 2014
-
Patent Title: Purine derivatives Nov. 25, 2014
-
Patent Title: Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses Nov. 18, 2014
-
Patent Title: Compounds and methods for treating bacterial infections Nov. 18, 2014
-
Patent Title: Co-crystals of a triazolo [4,5-d] pyrimide platelet aggregation inhibitor Nov. 11, 2014
-
Patent Title: Methods for treating obesity employing an sglt2 inhibitor Nov. 11, 2014
-
Patent Title: Inhaler cap strap Nov. 04, 2014
-
Patent Title: Immediate release tablet formulations Oct. 28, 2014
-
Patent Title: Compounds and their use as bace inhibitors Oct. 21, 2014
-
Patent Title: Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline Oct. 21, 2014
-
Patent Title: Method for preparing adenine compound Oct. 21, 2014
-
Patent Title: Maleate salts of a quinazoline derivative useful as an antiangiogenic agent Oct. 14, 2014
-
Patent Title: Pyrrolo[3,2-d]pyrimidin-4-one derivatives and their use in therapy Oct. 14, 2014
-
Patent Title: Inhibitors of protein kinases Sep. 23, 2014
-
Patent Title: Pyrazolylaminopyridine derivatives useful as kinase inhibitors Sep. 16, 2014
-
Patent Title: Process for preparing dipeptidyl peptidase iv inhibitors and intermediates therefor Aug. 19, 2014
-
Patent Title: Crystal forms of saxagliptin and processes for preparing same Aug. 12, 2014
-
Patent Title: Inhaler 624 Aug. 12, 2014
-
Patent Title: Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same Jul. 29, 2014
-
Patent Title: Pyrimidline derivatives having immune modulating properties that act via tlr7 for the treatment of viral or allergic diseases and cancers Jul. 01, 2014
-
Patent Title: Process for the manufacture of 4-fluoro-2-methyl-1h-indol-5-ol Jun. 17, 2014
-
Patent Title: Crystalline forms of n-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1r,2s)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide Jun. 10, 2014
-
Patent Title: Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors Jun. 03, 2014
-
Patent Title: Benzamide compounds useful as histone deacetylase inhibitors May. 27, 2014
-
Patent Title: Compound May. 27, 2014
-
Patent Title: Quinazoline derivatives as tyrosine kinase inhibitors May. 27, 2014
-
Patent Title: Pyrimidine sulphonamide derivatives as chemokine receptor modulators May. 13, 2014
-
Patent Title: Biphenyloxyacetic acid derivatives for the treatment of respiratory disease May. 13, 2014
-
Patent Title: Heterocyclic compounds as ccr2b antagonists Apr. 29, 2014
-
Patent Title: Compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation Apr. 15, 2014
-
Patent Title: Therapeutic agents Apr. 01, 2014
Federal grants, loans, and purchases
- $1,860 2025-12-29 00:00:00 Agency: Department of Health and Human Services
- $2,134 2025-12-29 00:00:00 Agency: Department of Health and Human Services
- $1,810 2024-12-30 00:00:00 Agency: Department of Health and Human Services
- $2,076 2024-12-30 00:00:00 Agency: Department of Health and Human Services
- $0 2024-04-24 00:00:00 Agency: Department of Veterans Affairs
- $2,023 2024-01-02 00:00:00 Agency: Department of Health and Human Services
- $1,764 2024-01-02 00:00:00 Agency: Department of Health and Human Services
- $20,322 2023-07-27 00:00:00 Agency: Department of Health and Human Services
Estimated quarterly amount awarded to AZN from public contracts
Recent insights relating to AZN
Recent picks made for AZN stock on CNBC
ETFs with the largest estimated holdings in AZN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AZN stock a Buy, Sell, or Hold?
- What is the price target for $AZN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AZN stock?
- Who owns the most shares of $AZN stock?
- What funds own $AZN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AZN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
AstraZeneca PLC (AZN) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for AstraZeneca PLC (AZN).
Quiver Premium charts AZN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at AZN, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|